Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Etoricoxib - Merck & Co.

Drug Profile

Etoricoxib - Merck & Co.

Alternative Names: Arcoxia; Exxiv; L 791456 - Merck; MK 0663; MK 663

Latest Information Update: 11 Apr 2020

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Merck & Co
  • Developer Merck & Co; University of Regensburg
  • Class Antirheumatics; Non-opioid analgesics; Pyridines; Small molecules; Sulfones
  • Mechanism of Action Cyclo-oxygenase 2 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Acute pain; Ankylosing spondylitis; Back pain; Dental pain; Dysmenorrhoea; Gouty arthritis; Musculoskeletal pain; Osteoarthritis; Postoperative pain; Rheumatic disorders; Rheumatoid arthritis
  • Phase III Surgical blood loss

Most Recent Events

  • 22 Jan 2019 Launched for Osteoarthritis in South Korea (PO) before January 2019
  • 15 Mar 2016 Biomarkers information updated
  • 21 Jul 2015 Discontinued - Phase-III for Ankylosing spondylitis in Canada (PO)
Restricted Access

If your organization has a subscription then there are several options available to help you access AdisInsight while working remotely. Contact us at AsktheExpert.AdisInsight@springer.com to find out more.
Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top